Evidence base for the efficacy and safety of flavonoids and the opinion of outpatient doctors in the focus of choice of approaches to treatment of ARI
Keywords:
ARI, flavonoids, treatment, outpatient practice, evidence-based medicineAbstract
Numerous publications, meta-analyzes and systematic reviews suggest different approaches to the treatment and prevention of ARI, therefore, in the practice of a doctor both in Ukraine and in other countries, there is a variety of schemes, protocols, regulations and professional recommendations for the management of these patients. Therefore, for competent, effective and safe treatment and prevention of ARI among national and world standards, a doctor needs to find the most optimal and effective algorithm for the management and treatment of viral infections of the respiratory tract, which ideally has a high level of evidence-based medicine and can be used in specific practice with the point of view of patient management and routing.
Purpose — to analyze the knowledge of the existing in Ukraine and the world of the regulatory framework and national protocols for the management of patients with ARI by general practitioners — family medicine, as well as to study the opinion of family doctors about the efficacy and safety of using flavonoids in the treatment and prevention of ARI.
Materials and methods. Anonymous survey of 149 family doctors in the city of Dnipro and the region was conducted in the current 2020. Among the respondents there were 55 doctors with a primary specialization in Pediatrics (37%), 37 doctors with a primary specialization in Internal Medicine (25%) and 57 with a primary specialization in Family Medicine (38%). The distribution normality was checked using the Kolmogorov+Smirnov test. Considering that 90% of the data were normally distributed, we used parametric statistics methods. To assess relationships between binary features, the ϕ-coefficient of mutual conjugation was used. The critical level of statistical significance was accepted as <5% (p<0.05).
Results. Family physicians are aware of current trends in the strategy of therapy and prevention of ARI. According to family doctors, drugs with the active substance Proteflazid, when prescribed for the treatment and prevention of acute respiratory viral infections, are safe (no toxic effect) and effective (according to our own observations) by reducing the duration and severity of the disease, the severity of fever and manifestations of intoxication syndrome, reducing the frequency of acute respiratory diseases (frequency rate per year), and that the above effects obtained in their own practice are associated with direct antiviral action, suppression of viral reproduction and multiple mechanisms of action of Proteflazid bioflavonoids. In addition to the professional opinion of family doctors, the opinion of parents about the effectiveness of drugs with the active substance Proteflazid for the treatment and prevention of ARI (feedback from a doctor) in the form of their positive feedback and a note that they are often used for self+treatment, and their choice is associated with the fact that Proteflazid preparations shorten the period of illness and, according to parents, children are less ill with ARI.
Conclusions. The presence of the proven antiviral action of flavonoids, as a class of polyphenolic compounds, and the fact that the flavonoids that make up Flavovir have a proven mechanism of antiviral activity, which is confirmed in clinical outpatient practice by the positive experience of primary care physicians (pronounced clinical efficacy) allows you to recommend Flavovir syrup for the treatment and prevention of influenza and seasonal ARI to children from birth.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of these Institutes. The informed consent of the doctors was obtained for conducting the studies.
References
Aziz N, Kim MY, Cho JY. (2018). Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. Journal of ethnopharmacology. 225: 342-358. https://doi.org/10.1016/j.jep.2018.05.019; PMid:29801717
Batiha GE, Beshbishy AM, Ikram M, Mulla ZS, El2Hack M, Taha AE, Algammal AM, Elewa Y. (2020). The Pharmacological Activity, Biochemical Properties, and Pharmacokinetics of the Major Natural Polyphenolic Flavonoid: Quercetin. Foods (Basel, Switzerland). 9 (3): 374. https://doi.org/10.3390/foods9030374; PMid:32210182 PMCid:PMC7143931
Kuznetsova L. (2017). Influence of flavonoids on the cellular immunity indices in children and adolescents with influenza and acute respiratory viral infections before and after treatment. «Laboratory diagnostics. Eastern Europe». 6 (3).
Li Y, Yao J, Han C, Yang J, Chaudhry MT, Wang S, Liu H, Yin Y. (2016). Quercetin, Inflammation and Immunity. Nutrients. 8 (3): 167. https://doi.org/10.3390/nu8030167; PMid:26999194 PMCid:PMC4808895
Mondal S, Rahaman ST. (2020). Flavonoids: A vital resource in healthcare and medicine. Pharm Pharmacol Int J. 8 (2): 91-104.
Mukvich OM, Kaminskaya TM. (2017). Preventive and therapeutic effectiveness of bioflavonoids in children with recurrent respiratory infections. CHILDS HEALTH. 12 (2): 124-129. https://doi.org/10.22141/2224-0551.12.2.2017.99767
Wang L, Song J, Liu A, Xiao B, Li S, Wen Z, Lu Y, Du G. (2020). Research Progress of the Antiviral Bioactivities of Natural Flavonoids. Natural products and bioprospecting. 10 (5): 271-283. https://doi.org/10.1007/s13659-020-00257-x; PMid:32948973 PMCid:PMC7500501
Wu W, Li R, Li X, He J, Jiang S, Liu S, Yang J. (2015). Quercetin as an Antiviral Agent Inhibits Influenza A Virus (IAV) Entry. Viruses. 8 (1): 6. https://doi.org/10.3390/v8010006; PMid:26712783 PMCid:PMC4728566
Yan H, Ma L, Wang H, Wu S, Huang H, Gu Z, Jiang J, Li Y. (2019). Luteolin decreases the yield of influenza A virus in vitro by interfering with the coat protein I complex expression. Journal of natural medicines. 73 (3): 487-496. https://doi.org/10.1007/s11418-019-01287-7; PMid:30758716
Downloads
Published
Issue
Section
License
The policy of the Journal “MODERN PEDIATRICS. UKRAINE” is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal “MODERN PEDIATRICS. UKRAINE” when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.